Published in

American Association for the Advancement of Science, Science Translational Medicine, 534(12), 2020

DOI: 10.1126/scitranslmed.aaw8275

Links

Tools

Export citation

Search in Google Scholar

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Journal article published in 2020 by Johanna M. Schafer ORCID, Brian D. Lehmann ORCID, Paula I. Gonzalez-Ericsson ORCID, Clayton B. Marshall ORCID, J. Scott Beeler ORCID, Lindsay N. Redman ORCID, Hailing Jin ORCID, Violeta Sanchez ORCID, Matthew C. Stubbs ORCID, Peggy Scherle ORCID, Kimberly N. Johnson, Quanhu Sheng ORCID, Joseph T. Roland ORCID, Joshua A. Bauer ORCID, Yu Shyr ORCID and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This study demonstrates the potential utility of BET and MEK inhibitors for advanced MYCN-expressing triple-negative breast cancer.